Case Report

Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports

Muhammad Firdaus, Arwinder Singh Gill, Dewi Aisiyah Mukarramah, Rini Andriani, Dian Cahyanti, Ahmad Faried

Departments of Neurosurgery, 1Plastic Surgery, 2Neurology and 3Pathology Anatomy, Dharmais National Cancer Hospital, Jakarta, 4Department of Neurosurgery and Oncology & Stem Cell Working Group, Universitas Padjadjaran, Bandung, Indonesia

E-mail: Muhammad Firdaus - firdausoenarya@gmail.com; *Arwinder Singh Gill - arwinsingh@hotmail.com; Dewi Aisiyah Mukarramah - daflako@gmail.com; Rini Andriani - andrianiini13@yahoo.com; Lenny Sari - lenny_sppa@yahoo.com; Dian Cahyanti - diancahyanti@gmail.com; Ahmad Faried - faried.fkup@gmail.com

*Corresponding author

Received: 29 May 17  Accepted: 12 April 18  Published: 15 May 18

Abstract

Background: Malignant peripheral nerve sheath tumors (MPNSTs) constitute a group of soft tissue neoplasm with neuroectodermal origin. Most cases are small at presentation and only some have been described reaching giant dimensions.

Case Description: We report two cases that were diagnosed and treated as giant MPNST of the scalp. Both patients had extensive lesion on the head with intracranial infiltration. Microsurgical resection was indicated and a vascularized free flap was used to cover the defect. During follow-up the tumors recurred and further surgical excision treatment by adjuvant radiation therapy was performed.

Conclusion: MPNSTs of the scalp are rare neoplasm of the peripheral nervous system. They are aggressive lesion that can recur and their management requires a multimodality approach.

Key Words: Malignant peripheral nerve sheath tumors, scalp, soft tissue tumor

INTRODUCTION

Malignant peripheral nerve sheath tumors (MPNSTs) of the scalp are rare neoplasms of the nervous system. These tumors are considered to be a subcategory of soft tissue sarcomas based on World Health Organization (WHO) classification on central nervous system (CNS) tumors because they arise from peripheral nerve sheaths and their cells of origin show divergent differentiation potentials. The lesion in CNS was first described by Kudo et al., and introduced into the English literature in 1983. It is currently classified by the WHO as MPNST in 2016, which further designates two subtypes of MPNST: epithelioid MPNST and MPNST with perineurial differentiation. A variety of terminologies including neurofibrosarcoma, neurogenic sarcoma, malignant schwannoma, and malignant neurilemmoma have been used to describe the tumor.

MPNSTs are very rare tumors with incidents of approximately 0.001% in the population; these tumors usually affect the proximal extremities and trunk and are very rare in the head/scalp and neck and these tumors behave in a highly malignant fashion and they are associated with a poor prognosis with only about 30% of patients surviving a 5-year survival rate.
The association of MPNST with neurofibromatosis type 1 (NF-1) has been reported; 20–50% of patients with MPNST also have NF-1, and besides de novo cases MPNST are usually seen as a result of malignant transformation of a preexisting plexiform neurofibroma.

In this report, we present two cases adding the evidence of scalp MPNST in world literature that were diagnosed and treated as giant MPNST of the scalp. Patients underwent microsurgery and adjuvant radiotherapy.

CASE REPORTS

Case 1
A 45-year-old male presented with painless and progressive swelling on the right frontal region over 2 years prior to examination. According to patient history, the “swelling” started over his eyebrow and progressively increased in size. He underwent a biopsy at an outside facility and the pathology report diagnosed neurofibroma but patient failed to follow-up. He was later referred to our hospital after the lesion enlarged in size and he had developed difficulties opening his eyes. He had no history of trauma, bone pain, systemic disease, or neurological symptoms. Physical examination found an extensive scalp lesion that measured 30 × 20 cm in size, extending from the right orbital rim toward the contralateral side and the parietal region. Upon palpation the lesion was firm but without any tenderness [Figure 1]. The skin on the tumorous area was adherent to the underlying soft tissue and the lesion was immobile. There was no visible venous dilatation or any audible bruit over the lesion. A small post biopsy scar was present at the middle of the lump. Neurological examination was unremarkable and the patient did not bear any signs of NF-1 as well as in their family tree.

Computed tomography (CT) scan of the head revealed a calvarial soft tissue mass predominantly located in right frontoparietal with infiltrating mass on the frontal region and associated right frontal bone defect [Figure 2a and b]. Magnetic resonance imaging (MRI) of the brain revealed a soft tissue mass that was iso-hypointense on T1 showing lobulated mass at frontal region [Figure 3a], which enhanced homogeneously after contrast administration [Figure 3b]. The mass extends to the frontal base viewed by coronal plane [Figure 3c] and various intensity on T2 imaging [Figure 3d]. The tumor showed extension from extracranial compartment through the bony defect into the right frontal lobe and frontal base. The decision was made to pursue resection.

The patient was positioned supine with back slightly elevated 20° and without any head fixation. A wide marginal excision with 4 cm distance from neoplasm margin was performed. At surgery, tumor tissue was found to be soft, fleshy, moderately vascular, and mostly encapsulated with some areas displaying ill-defined margins. The mass was eroding through the internal table of the bone and infiltrated the dura mater as well as the intradural compartment. The mass was highly vascular and bled easily when touched. The bone at the right frontal region appeared moth-eaten and was removed with rongeurs until a normal hard and thick border was identified. A wide intracranial portion of the lesion was removed without any involvement of brain parenchyma, and a fascia lata graft was used for duroplasty. The postoperative bone defect measuring 10 × 10 cm was closed using a titanium mesh. A vascularized free flap was raised from anterolateral thigh and sewn in by the plastic surgeon to close the skin defect. The patient’s neurological status remained intact postoperatively. He was discharged from the hospital uneventfully.
Over a period of 6 months, the patient was seen in regular follow-up when a recurrence was seen on routine imaging and also new complaint of ptosis on left side. The images show local recurrence on right frontal lobe; interestingly, a new lesion was prominent on contralateral cavernous sinus [Figure 4]. Patient underwent surgery for the right frontal lobe mass and 20 gray external beam radiosurgery for cavernous sinus lesion. There was partial response as the ptosis complaint got better and mass shrink nearly 50% of its size. After 2 years the tumor recurred again on both right frontal and also cavernous sinus, but the patient refused any other medical intervention. Patient died two-and-a-half years after initial diagnosis of this disease.

Case 2
A 49-year-old male patient came to our hospital with a tumorous growth located in the frontal region of his head, which developed over approximately 3 years prior to presentation. He had undergone an operation in another hospital about 2 years earlier but the lump had been growing rapidly over the preceding 6 months. Pathologic analysis revealed malignant schwannoma. On physical examination, we encountered two firm, noncompressible, not tender, nonpulsatile masses that measured approximately 6 × 5 cm and 8 × 8 cm in the frontal region with head CT scan reveal bone discontinuity due to bony destruction [Figure 5].

There were no clinical signs suggesting neurofibromatosis and the family history was negative. The patient underwent microsurgical resection via a frontal craniotomy followed by plastic and reconstructive in a single surgery. The involved bone and a 2-cm margin of healthy tissue were excised together with the tumor mass. The involved bone was brittle and soft, so it rongeured until thick and healthy bone was encountered. There was no infiltration of the underlying dura mater and the lesion could be completely excised en bloc. Cranioplasty was required to close the resulting 4 × 4 cm calvarial defect. After excising the mass, the scalp defect measured approximately 15 × 12 cm and the reconstruction was completed using a myocutaneous flap with a muscle cuff along with the vascular pedicle [Figure 6a and b]. The graft was taken from anterolateral thigh and femoral circumflexa artery – superficial temporal artery anastomosis was performed. The wound healed well and no surgical complications arose. Conventional radiotherapy of 50 gray was performed 2 months after the surgery. The final pathological diagnosis of MPNST was made based on examination of the surgical specimen. Light microscopy revealed that the tumor cells were monomorphic spindle-shaped cells with frequent mitotic figures [Figure 6c]. Immunohistochemistry revealed positive immunoreactivity with S-100 and ki-67 protein [Figure 6d and e]. During 1 year follow-up and 3 months interval MRI, no recurrence was seen.

DISCUSSION
The scalp consists of five layers: skin, connective tissue, aponeurosis (epicranial tissue), loose connective tissue, and periosteum. Any of these tissue layers may be associated with tumors, either benign or malignant.[15]

MPNSTs are rare tumors with an incidence of approximately 0.001% in the general population with slight male predominance and accounting for 5–10% of all soft tissue sarcomas.[4,16] MPNST is located mainly in the trunk and extremities, such as the buttocks, thighs, brachial plexus, sciatic nerve, and paraspinal region. Primary MPNST occurring in the scalp appears extremely rare,[15] and in 2013, Wang et al. reported only 16 such cases in the English literature.[17]
The etiology is unknown but they have a known association with NF-1,[5] an autosomal-dominant disorder that involves the NF-1 tumor suppressor gene, which is located on chromosome 17. Up to 50% of MPNSTs occur in patients with NF-1, and there is a higher incidence in patients with a history of radiation exposure.[17,18]

The initial clinical features of MPNST of the scalp are somewhat atypical when compared to other peripheral MPNSTs. Most patients present with a gradually increasing mass in the scalp (cutaneous or subcutaneous). Symptoms of headache, vomiting, seizures, vertigo, visual impairment, or focal neurological deficits may occur in patients with giant MPNST of the scalp if there is any intracranial extension of the tumor.[2,7]

Diagnostic imaging plays a significant role in determining tumor resectability, assessing surgical risks, and in planning reconstruction. Sequential MRI is necessary for assessing the patient for possible tumor recurrence. CT scan imaging shows the extent of bony involvement, as in both the cases there was destruction of cortical bone. MRI is the investigative tool of choice because it defines the anatomic relationships between the lesion and the adjacent soft tissues, including muscular, vascular, and neural structures.[7,18]

Microscopically, MPNST is a densely cellular tumor that shows fascicular areas with alternate myxoid regions. The swirling arrangement of intermixed dense and myxoid areas has been described as a marbleized pattern.[10] The cells may be spindle-shaped with irregular contours. Malignancy is suggested by features such as invasion of surrounding tissues, invasion of vascular structures, nuclear pleomorphism, necrosis, and mitotic activity. S-100 immuno-positivity has been reported in approximately 50–90% of MPNST cases.[8] In general, a soft tissue panel of antigen stains is used to help exclude other spindle cell lesions and to confirm the diagnosis of MPNST.[8,10,18]

The current management of MPNST is comparable to that of other soft tissue tumors.[10,17] Surgery is pivotal in the treatment of MPNST of the scalp. The goal of surgery has to be to achieve complete excision of the tumor with wide (negative) margins (≥2 cm) using frozen section pathology analysis during surgery.[17] After extensive resections, scalp defects are common and reconstruction needs to be undertaken by employing cutaneous or myocutaneous flaps. To this end, a plastic and reconstructive surgery team should be involved, as was done in both of our cases.[4,17]

MPNSTs are aggressive malignancies treated in the same way as other high-grade sarcomas. There are no specific guidelines for MPNST of the head or scalp. These guidelines usually follow soft tissue sarcomas. For those patients with resectable disease, a wide excision through normal uninvolved tissues is the surgical procedure of choice. Defining a rts and a literature reversal, but with the addition of effective adjuvant therapy (e.g. radiotherapy) a tumor-free margin (R0) may be adequate. Where a wide excision is not possible due to anatomical constraints, a planned marginal or microscopically positive margin against a critical structure, plus radiotherapy, for intermediate and high-grade tumors, may be an appropriate means of achieving tumor control while maintaining physical function.[3]

Although complete excisions can seemingly be achieved during surgery, local recurrence occurs frequently and will need further radiotherapy and/or chemotherapy. Local recurrences have been reported in as many as 52–88.9%
of MPNSTs for different sites.\textsuperscript{[17]} Overall survival for these aggressive tumors is often limited and was reported to be around only 30\% at 5 years.\textsuperscript{[3,10,12,17]}

**CONCLUSION**

We describe two rare cases of giant primary MPNST of the scalp that were treated surgically followed by radiotherapy. MPNST should be considered as a differential diagnosis of an enlarging scalp soft tissue lesion and these tumors can show bony and intracranial involvement. MPNSTs are aggressive lesion and a multimodal approach is recommended for management.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: The clinical spectrum and outcome of treatment. Neurology 2003;61:696-8.
2. Bouhafa T, Elmazghi A, Baissel H, Fatmi HE, Amarti A, Hassouni K. Malignant peripheral nerve sheath tumors of the scalp: Case report and review of literature. Int J Clin Med 2014;5:916-20.
3. Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 2016;6:20.
4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-21.
5. Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res 2012;2:17.
6. Farid M, Demiçco EG, García R, Ahn L, Merola PR, Ciolfi A, Maki RG. Malignant peripheral nerve sheath tumors. Oncologist 2014;19:193-201.
7. George E, Swanson PE, Wick MR. Malignant peripheral nerve sheath tumours of the skin. Am J Dermatopathol 1989;11:213-21.
8. Guo A, Liu A, Wei L, Song X. Malignant peripheral nerve sheath tumors: differentiation patterns and immunohistochemical features—a mini-review and our new findings. J Cancer 2012;3:303-9.
9. Hajdu SI. Peripheral nerve sheath tumors. Histogenesis, classification, and prognosis. Cancer 1993;72:3549-52.
10. Jhawar SS, Mahore A, Goel N, Goel A. Malignant peripheral nerve sheath tumour of scalp with extradural extension: Case report. Turk Neurosurg 2012;22:254-6.
11. Kudo M, Matsumoto M, Terao H. Malignant nerve sheath tumor of acoustic nerve. Arch Pathol Lab Med 1983;107:293-7.
12. Kumar P, Jaiswal S, Agrawal T, Verma A, Datta NR. Malignant peripheral nerve sheath tumor of the occipital region: Case report. Neurosurgery 2007;61:E1334-45.
13. Latham K, Buchanan EP, Suver D, Gruss JS. Neurofibromatosis of the head and neck: Classification and surgical management. Plast Reconstr Surg 2015;135:945-55.
14. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016;131:803-20.
15. Teles AMM, De Lima BA, Costa TCC, Lins RC, Barbosa GHTS, et al. Giant malignant peripheral nerve sheath tumor of the scalp. Acta Neurol Taiwan 2012;21:133-5.
16. Wanebo JE, Malik JM, VandenBerg SR, Wanebo HJ, Driesen N, Persing JA. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 1993;71:1247-53.
17. Wang J, Ou SW, Guo ZZ, Wang YJ, Xing DG. Microsurgical management of giant malignant peripheral nerve sheath tumor of the scalp: Two case reports and a literature review. World J Surg Oncol 2013;11:269.
18. Woodruff JM, Selig AM, Crowley K, Allen PW. Schwannoma (neurilemoma) with malignant transformation. A rare, distinctive peripheral nerve tumor. Am J Surg Pathol 1994;18:882-95.